Satellos Bioscience Inc. Common Stock (MSLE)
Stock · NASDAQ · Health Care
$6.7as of 10/16/2026
Price chart
Active signals
MSLE Signal Track Record
How signals performed across all stocks →What MSLE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 27 | -8.1% | 44% | June 29, 2026 |
| 200-Day Moving Average TouchActive now | 22 | +2.5% | 55% | September 23, 2026 |
| Bollinger Band Breakdown | 15 | +11.2% | 73% | September 23, 2026 |
| Volume Spike | 10 | +4.3% | 60% | October 8, 2026 |
| Any 20-session window (baseline) | +0.2% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MSLE
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidat…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 18
- Website
- satellos.com/
Fundamentals
- 1-day range
- $6.52$7.06
- Market cap
- $209.77M
- P/E (trailing)
- —
- P/E (forward)
- -2.43
- EPS (trailing)
- $-1.98
- Dividend yield
- —
- Beta
- 1.57
- Avg. volume
- 47.2K
Forecasts
6 analyst ratings
Satellos Bioscience Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MSLESatellos Bioscience Inc. Common Stock$6.46▼ 5.56%Market cap $209.77MP/E —$7.56$18.98
- GLSIGreenwich LifeSciences Inc. Common Stock$14.55▼ 5.03%Market cap $209.02MP/E —$7.78$34.1
- KROSKeros Therapeutics Inc. Common Stock$10.66▼ 3.96%Market cap $211.16MP/E —$9.69$22.55
- NERVMinerva Neurosciences Inc Common Stock$2.35▼ 2.89%Market cap $206.85MP/E —$2.31$12.46
- ANTXAN2 Therapeutics Inc. Common Stock$3.38▼ 6.11%Market cap $218.98MP/E —$1$7.19
- IMUXImmunic Inc. Common Stock$6.97▼ 1.83%Market cap $198.06MP/E —$5.06$17.43
- NBPNovaBridge Biosciences American Depositary Shares$1.26▼ 2.33%Market cap $196.15MP/E —$1.26$6.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MSLE Satellos Bioscience Inc. Common Stock | $209.77M | — | $6.46 | ▼ 5.56% | $7.56$18.98 |
| GLSI Greenwich LifeSciences Inc. Common Stock | $209.02M | — | $14.55 | ▼ 5.03% | $7.78$34.1 |
| KROS Keros Therapeutics Inc. Common Stock | $211.16M | — | $10.66 | ▼ 3.96% | $9.69$22.55 |
| NERV Minerva Neurosciences Inc Common Stock | $206.85M | — | $2.35 | ▼ 2.89% | $2.31$12.46 |
| ANTX AN2 Therapeutics Inc. Common Stock | $218.98M | — | $3.38 | ▼ 6.11% | $1$7.19 |
| IMUX Immunic Inc. Common Stock | $198.06M | — | $6.97 | ▼ 1.83% | $5.06$17.43 |
| NBP NovaBridge Biosciences American Depositary Shares | $196.15M | — | $1.26 | ▼ 2.33% | $1.26$6.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24Benzinga · 10/8/2026
- Satellos Granted Composition of Matter Patent for ForazapadinYahoo · 10/5/2026
- Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor PlatformBenzinga · 10/5/2026
- Satellos Bioscience Completes Enrollment in Phase 2 Basecamp TrialYahoo · 9/30/2026
- Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular DystrophyYahoo · 9/30/2026
- Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of AgeBenzinga · 9/30/2026
- Satellos Receives FDA Clearance For FSHD Investigational New Drug ApplicationYahoo · 9/24/2026
- Satellos Receives FDA Clearance to Study Forazapadin in FSHDYahoo · 9/24/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 7.60M
- Total value held
- $42.62M
- Institutional holders
- 31
- Unknown938.7K
- Unknown892.1K
- Unknown813.7K
- Unknown690.8K
- Unknown500.4K
- Unknown489.2K
- Unknown475.0K
- Unknown414.4K
- Unknown387.8K
- Unknown380.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MSLE receives FDA clearance for Forazapadin IND in FSHD
Satellos Bioscience announced that the U.S. Food and Drug Administration cleared its investigational new drug application for Forazapadin to be studied in patients with facioscapulohumeral muscular dystrophy. The clearance permits the company to start clinical trials for the therapy. The company also disclosed a partnership with the FSHD Canada Foundation that will provide non‑dilutive financing to support the clinical development program.
MSLE receives FDA clearance for Forazapadin IND in FSHD. Satellos Bioscience announced that the U.S. Food and Drug Administration cleared its investigational new drug application for Forazapadin to be studied in patients with facioscapulohumeral muscular dystrophy. The clearance permits the company to start clinical trials for the therapy. The company also disclosed a partnership with the FSHD Canada Foundation that will provide non‑dilutive financing to support the clinical development program.